All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.

More information on our cookie policy.

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Aging
    • Biosimilars
    • Artificial intelligence
    • Coronavirus
    • IVDs on the rise
    • Radiopharmaceuticals
    • Science '22 in Review
    • Top Biopharma Trends of 2022
    • Top Med-tech Trends of 2022
    • Premium reports
      • BioWorld Financings Reports
      • Disease Incidence & Prevalence Summaries

BioWorld. Link to homepage.

  • sign in
  • Sign Out
  • My Account
Subscribe
BioWorld - Wednesday, May 31, 2023
Home » Topics » Asia-Pacific » China

China
China RSS Feed RSS

China greenlights CSPC’s mRNA COVID-19 vaccine for emergency use

March 23, 2023
By Zhang Mengying
No Comments
CSPC Pharmaceutical Group Ltd.’s COVID-19 mRNA vaccine, SYS-6006, has been included for emergency use by the NMPA, the company said on March 22, marking the first domestically developed COVID-19 mRNA vaccine approved for use in China.
Read More

Biohaven acquires early stage TYK2/JAK1 inhibitor from Highlightll in $970M deal

March 23, 2023
By Doris Yu
No Comments
Biohaven Ltd. has acquired global rights, excluding China, from Highlightll Pharmaceutical Co. Ltd. to develop and commercialize a dual inhibitor of tyrosine kinase 2 (TYK2) and JAK1, BHV-8000 (TLL-041), for the treatment of brain disorders in a deal worth up to $970 million.
Read More
Cancer cell and target
Newco news

Likang cleared for China’s first clinical trial testing personalized neoantigen-targeted cancer vaccine

March 21, 2023
By Doris Yu
No Comments
Likang Life Sciences Holdings Ltd. received approval from China’s NMPA to start a clinical trial of its candidate, LK-101 injection, for advanced solid tumors. The company claims this is the first personalized neoantigen vaccine and mRNA editing product to enter the clinic in China.
Read More

NMPA accepts enfortumab vedotin application from Astellas

March 21, 2023
By Doris Yu
No Comments
The NMPA accepted a BLA from Astellas Pharma Inc. for enfortumab vedotin, which is designed for the treatment of patients with locally advanced or metastatic urothelial cancer who previously received treatment with a PD-1/L1 inhibitor and platinum-based chemotherapy.
Read More
Health Guard

Health Guard Biotech nets $43M in Beijing IPO, shares plunge 15.43%

March 21, 2023
By Doris Yu
No Comments
Health Guard Biotechnology Inc. raised ¥294 million (US$43 million) in an IPO on the SME-focused Beijing Stock Exchange, with the funds going to push the development of its HPV vaccines.
Read More

Abbisko’s pimicotinib advances to pivotal phase III trials in U.S., China

March 21, 2023
By Tamra Sami
No Comments
Abbisko Therapeutics Co. Ltd.’s colony-stimulating factor 1 receptor (CSF-1R) inhibitor, pimicotinib (ABSK-021), is advancing from phase I trials to pivotal phase III trials in patients with tenosynovial giant cell tumors (TGCT) in the U.S. and China following clearance from both regulators.
Read More

Abbisko’s pimicotinib advances to pivotal phase III trials in U.S., China

March 16, 2023
By Tamra Sami
No Comments
Abbisko Therapeutics Co. Ltd.’s colony-stimulating factor 1 receptor (CSF-1R) inhibitor, pimicotinib (ABSK-021), is advancing from phase I trials to pivotal phase III trials in patients with tenosynovial giant cell tumors (TGCT) in the U.S. and China following clearance from both regulators.
Read More
Health Guard

Health Guard Biotech nets $43M in Beijing IPO, shares plunge 15.43%

March 16, 2023
By Doris Yu
No Comments
Health Guard Biotechnology Inc. raised ¥294 million (US$43 million) in an IPO on the SME-focused Beijing Stock Exchange, with the funds going to push the development of its HPV vaccines.
Read More
Immuno-oncology

Henlius’ agonistic anti-OX40 humanized monoclonal antibody HLX-51 cleared to enter clinic in China

March 16, 2023
No Comments
Shanghai Henlius Biotech Inc. has received...
Read More

Neuboron performs boron neutron capture therapy in Chinese trial

March 15, 2023
By Doris Yu
No Comments
In its first trial designed to evaluate boron neutron capture therapy (BNCT) in the treatment of advanced refractory malignant tumors, Neuboron Medtech Ltd. has performed 14 irradiations on a dozen patients.
Read More
Previous 1 2 3 4 5 6 7 8 9 10 11 … 123 124 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for May 30, 2023.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for May 30, 2023.
  • FDA approved icons and medical professional

    Genmab, Abbvie to join Roche with FDA nod for CD20 bispecific in lymphoma

    BioWorld
    Five months after the first anti-CD20xCD3 T-cell engaging bispecific antibody, Roche Holding AG’s Lunsumio (mosunetuzumab), cleared U.S. FDA approval for...
  • Illustration of pancreas

    Gene therapy to reverse T2D shows proof of concept at ASGCT

    BioWorld
    The most ambitious objective of any treatment is to eradicate the disease, acting on its origin to cure it instead of treating its symptoms. This is the purpose...
  • Clinical data illustration

    Medtronic, Philips, Edwards late-breaking study data spotlighted at EuroPCR

    BioWorld MedTech
    Among the many companies presenting data at the EuroPCR conference in Paris, several late breaking trials from heavy hitters Medtronic plc, Royal Phillips NV and...
black cortellis ad

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
Follow Us

Copyright ©2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing